The effect of tislelizumab on complete and pathological complete response in non-small cell lung cancer: a systematic review and meta-analysis
{{output}}
Background: Immune checkpoint inhibitors have transformed non-small cell lung cancer (NSCLC) treatment, and while overall survival (OS) and progression-free survival (PFS) are well-established, a comprehensive meta-analysis focus... ...
